BACKGROUND AND AIM: Complicated Cataract is frequently associated with @entity6391 ( @entity6391 ). This @entity989 is a great cause of @entity227 , and @entity231 surgery may resolve partially the situation and restore sight. Unfortunately, in this case there is a very high incidence of @entity231 ( @entity231 ) ranging in several studies a percentage of 100% at six months. Our goal was to evaluate whether the high incidence of @entity231 is associated to specific type of Intraocular Lens (IOL) biomaterials. MATERIALS AND METHODS: This observational retrospective study deals with 75 eyes of 43 @entity1 affected with @entity6391 who underwent to @entity231 surgery with posterior chamber IOL implants (40% ECCE and 60% Phaco). Selected biomaterials were: 30 @entity4625 ( @entity4625 ), 11 @entity1346 , 34 acrylic. Observations were performed with retro-illumination camera and when recorded capsular @entity82 a @entity231 YAG laser capsulotomy was made. The @entity1 were controlled at 3-6-12 months after the initial surgical treatment. RESULTS: At three months of follow up, 80% of @entity1 with @entity4625 , 81.8% @entity1346 implants underwent to YAG capsulotomy while only 44% of acrylic type. At six months of follow-up 83.3% of @entity1 with @entity4625 and 81.8% @entity1346 implants underwent to YAG capsulotomy while only 49.88% of acrylic type. At 12 months of follow up 89.9% of @entity1 with @entity4625 and 90.95 @entity1346 implants underwent to YAG capsulotomy while only 52.82% of acrylic type. CONCLUSIONS: We could not be able to differentiate incidence between different brand type of lens in @entity4625 . For Acrylic lens instead we noted an incidence of @entity231 of 41.38% with hydrophobic material and 60.0% of hydrophilic material. In conclusion to avoid massive @entity231 in @entity6391 , our experience is statistically significant, in fact the protective action of smooth material hydrophobic lens avoids the epithelial growth and @entity82 towards the center of @entity227 .

Posterior capsule opacity in XXXX according to different biomaterials of intraocular lenses: Our clinical experience.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4625 :: ('MESH:D019904', 'Chemical') :: ['PMMA', 'Poly (methyl methacrylate)'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual axis', 'visual impairment'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract', 'Posterior Capsule Opacity', 'PCO'] @entity6391 :: ('MESH:D012174', 'Disease') :: ['Retinitis Pigmentosa', 'RP'] @entity1346 :: ('MESH:D012828', 'Chemical') :: ['silicone'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy']
@entity6391 :: (MESH:D012174,Disease) :: ['Retinitis Pigmentosa']
